In the case of a woman with metastatic non–small cell lung cancer, answer question of what you would do in terms of treatment and management, as well as questions about your practice.
Share your perspective on a patient case with related polling questions about your practice and opinions on treatment in non–small cell lung cancer (NSCLC). All oncology practices see different patients and have their own protocols for treatment. In this case, chemoimmunotherapy regimens are considered from the phase 3 POSEIDON (NCT03164616), EMPOWER-Lung 3 (NCT03409614), KEYNOTE-407 (NCT02775435), and CheckMate 9LA(NCT03215706) trials.
CASE SUMMARY
What percentage of patients do you treat with advanced stage or metastatic squamous NSCLC?
CASE CONTINUED
Should patients with metastatic NSCLC without actionable driver mutations and PD-L1 greater than 50% receive chemoimmunotherapy?
Which combination therapy would you use for this patient?
CASE CONTINUED
Have you ever used nivolumab/ipilimumab plus 2 cycles of chemotherapy in practice?
CASE CONTINUED
For this patient with grade 3 diarrhea, your next step is to:
CASE CONTINUED
Genetics and Ring Sideroblasts Impact ESA-Refractory Anemia in MDS
September 5th 2024During a Case-Based Roundtable® event, Azra Raza, MD, discussed a patient case of myelodysplastic syndrome first treated with erythropoiesis-stimulating agent in the second article of a 2-part series.
Read More
Lower-Intensity Talquetamab Dose Shows Potential in Multiple Myeloma
August 30th 2024During a Case-Based Roundtable® event, Tara K. Gregory, MD, discussed the MonumenTAL-1 trial of talquetamab in patients with relapsed/refractory multiple myeloma in the first article of a 2-part series.
Read More
Nivolumab Combinations Debated for a Patient With Metastatic Melanoma
August 28th 2024During a Case-Based Roundtable® event, Hussein A. Tawbi, MD, PhD, and participants considered nivolumab/ipilimumab and nivolumab/relatlimab as options for a patient with metastatic melanoma in the first article of a 2-part series.
Read More